Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Co-Diagnostics reports Q1 results, focuses on growth and innovation

Co-Diagnostics reported mixed financial results for Q1 2024, with revenue decrease but gross profit increase.
The company is strategically focused on commercialization efforts, product development, and managing expenses for growth.
Despite facing challenges such as net losses and operational complexities, Co-Diagnostics remains optimistic about future opportunities.
With a strong cash position and ongoing FDA submissions, Co-Diagnostics is poised for potential revenue growth and market expansion.

Co-Diagnostics reports Q3 revenue decline, focuses on global expansion

Co-Diagnostics faces financial challenges with a significant net loss in Q3 2024 but maintains a strong focus on advancing its testing platforms and expanding manufacturing capabilities.
Strategic opportunities in international market expansion and test development supported by grants present avenues for growth and market penetration.
Efforts to manage cash position through efficient spending and operational efficiencies underscore the company's commitment to future commercial success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Royal Caribbean Cruises

Keep an eye on these stocks during the COVID-19 crisis -- there might be a massive profit opportunity.

2 High-Risk, High-Reward Stocks to Add to Your Watchlist

The company's shares have soared though it has offered few specifics about the financial impact its COVID-19 products are having.

Co-Diagnostics Reports Surge in Demand for Coronavirus Tests

Alpha Pro Tech

BioCryst Pharmaceuticals

GenMark Diagnostics

These companies have different products related to the coronavirus outbreak but share one thing in common: Their stocks are all rising.

Why These 4 Coronavirus-Focused Stocks Are Soaring Today

Co-Diagnostics Inc (NASDAQ: CODX) shares have been on a roll following the outbreak the COVID-19, the latest coronavirus strain that has stirred fears and anxiety.

Co-Diagnostics Says COVID-19 Test Kit Demand Surges In Recent Weeks

So long as coronavirus keeps spreading, CODX stock will keep working -- but the virus won't keep spreading forever.

Up 2000% on Coronavirus Worries, CODX Stock Is a Short-Term Buy

Moderna

Vaxart

Global markets lost $6 trillion in the week ended Feb 29 as coronavirus triggered sharp selloff. Here's how to play the dip.

3 Correction-Defying Bets to Buy as Markets Brave Coronavirus

Apple

Inovio Pharmaceuticals

Professional money managers are looking to buy stocks that act as a hedge against coronavirus threat, or those that simply benefits from the particular event.

4 Top Stocks to Win Big From the Coronavirus Pandemic (Revised)

Flawed coronavirus test kits from the Centers for Disease Control severely limited the number of U.S. patients screened in January and February.

Faulty COVID-19 Test Kits Tilt Scales in Coronavirus's Favor

Allied Healthcare Products

Gilead Sciences

Teladoc

Zoom Video

Financial markets everywhere are plunging, but these seven coronavirus stocks have rallied as the virus has spread.
The post 7 Red-Hot Coronavirus Stocks Rallying While the Market Plunges appeared first on InvestorPlace.

7 Red-Hot Coronavirus Stocks Rallying While the Market Plunges

Shares are taking a breather following a downgrade by an analyst at Maxim Group.

Why Co-Diagnostics Stock Is Crashing Today

Co-Diagnostics Inc. (NASDAQ: CODX) is a small-cap stock that is far from a household name, but it has received much added exposure after becoming the first of the molecular diagnostics companies given a CE-Marking for its coronavirus test.

Can Co-Diagnostics Dominate Coronavirus News Against New Competition

Shares of Co-Diagnostics Inc. CODX, +34.62% tumbled 14% in premarket trading Tuesday, to pull back from the previous session's record close, after Maxim Group analyst Jason McCarthy downgraded the molecular diagnostics company citing concerns over valuation after the recent rocket ride up.

Co-Diagnostics' stock tumbles after Maxim downgrades following massive run up in price

American Airlines

Boeing

Chevron

Norwegian Cruise Line

Netflix

Regeneron Pharmaceuticals

Here're the big winners and losers since the coronavirus outbreak brought the U.S. bull market to a standstill.

Best & Worst Performing Stocks in Coronavirus Outbreak

Investors liked the FDA's aggressive move to allow labs to use coronavirus tests, including one developed by Co-Diagnostics.

Why Co-Diagnostics Stock  Is Jumping Today

Co-Diagnostics, Inc. (NASDAQ: CODX) shares were trading higher Monday after the company announced it will provide COVID-19 tests to U.S.

Co-Diagnostics To Provide Coronavirus Tests To Certified US Labs After FDA Policy Change

Trillium Therapeutics

Vir Biotechnology

Small-cap biotechs focused on virus treatments and cures have soared in recent weeks, but most folks should avoid these risky stocks.

Small-Cap Biotech Stocks Soar on Coronavirus Speculation

4 Top Stocks to Win Big From the Coronavirus Pandemic

Novavax

Progress with new COVID-19 tests and experimental vaccines in early-stage development sent these stocks flying higher.

3 Coronavirus Stocks That Soared Last Week

Clorox

These seven stocks could protect your portfolio against the SARS-CoV-2 outbreak.

7 Stocks to Buy as a Hedge Against The Coronavirus Threat

Some of the top stocks in 2020 are the companies that are fighting the coronavirus.

3 Small-Caps That Are Soaring Because of Coronavirus Panic

I say this now, but the full scope of that realization only really hit me during Thursday’s session when, right on the opening bell, I fell into the red by more than $7,000 on just 3,000 shares of Co-Diagnostics, Inc.

From Blue Chips To Penny Stock, The Market's Physics Have Changed

While most stocks and markets have taken big hits, these three coronavirus stocks have been among the most explosive opportunities.
The post 3 Coronavirus Stocks to Own Until the Fear Fades appeared first on InvestorPlace.

3 Coronavirus Stocks to Own Until the Fear Fades

Stamps.com

Uniti Group

Wall Street has entered into the correction territory after steep coronavirus-induced selloffs in February. But these stocks have gained massively.

Market in Correction: 5 Stocks Resist Virus Attack in February

Hint: It's not Inovio, Moderna, or Novavax.

This Under-the-Radar Stock Is the Biggest Winner From the Coronavirus Outbreak

Shares of Co-Diagnostics Inc. CODX, +54.69% , a molecular diagnostics company that has developed a test for the coronavirus, rose another 57% on Thursday, bringing its month-to-date gains to 333%, after the company said it has received a CE Mark for its test.

Co-Diagnostics stock soars 57% on high hopes for its coronavirus test

News for Co-Diagnostics Stock (CODX)